Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Grows By 65.3%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,118,479 shares, a growth of 65.3% from the December 31st total of 676,713 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 2,519,261 shares, the days-to-cover ratio is presently 0.4 days. Based on an average trading volume of 2,519,261 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.0% of the shares of the company are short sold.

VolitionRX Price Performance

Shares of VolitionRX stock opened at $0.29 on Monday. The business has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.47. VolitionRX has a 1 year low of $0.22 and a 1 year high of $0.94. The company has a market capitalization of $37.33 million, a price-to-earnings ratio of -1.24 and a beta of 1.28.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.